269 related articles for article (PubMed ID: 33250966)
1. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis.
Yang L; Dong XZ; Xing XX; Cui XH; Li L; Zhang L
World J Gastrointest Oncol; 2020 Nov; 12(11):1346-1363. PubMed ID: 33250966
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
Ni X; Xing Y; Sun X; Suo J
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
Wang BC; Zhang ZJ; Fu C; Wang C
Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of PD‑1/PD‑L1 inhibitors combined with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis.
Su S
Oncol Lett; 2023 Sep; 26(3):373. PubMed ID: 37564826
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhuansun Y; Huang F; Du Y; Lin L; Chen R; Li J
J Thorac Dis; 2017 Mar; 9(3):655-665. PubMed ID: 28449473
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
[TBL] [Abstract][Full Text] [Related]
7. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
Chen C; Zhang F; Zhou N; Gu YM; Zhang YT; He YD; Wang L; Yang LX; Zhao Y; Li YM
Oncoimmunology; 2019; 8(5):e1581547. PubMed ID: 31069144
[No Abstract] [Full Text] [Related]
9. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
11. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Zheng Z; Guo Y; Zou CP
Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Huang J; Zhang Y; Sheng J; Zhang H; Fang W; Zhan J; Zhou T; Chen Y; Liu L; Zhang L
Onco Targets Ther; 2016; 9():5867-5874. PubMed ID: 27713640
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Wang X; Bao Z; Zhang X; Li F; Lai T; Cao C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2017 Aug; 8(35):59901-59914. PubMed ID: 28938692
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wen W; Zhang Y; Zhang H; Chen Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):969-978. PubMed ID: 35771261
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.
Wang BC; Cao RB; Fu C; Chen WB; Li PD; Lin GH; Qian XJ; Li YT; Liu Q
Oral Oncol; 2020 May; 104():104640. PubMed ID: 32182550
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
Huang G; Sun X; Liu D; Zhang Y; Zhang B; Xiao G; Li X; Gao X; Hu C; Wang M; Ren H; Qin S
Oncotarget; 2018 Jan; 9(3):4239-4248. PubMed ID: 29423118
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
Liu BW; Shang QX; Yang YS; Chen LQ
Front Oncol; 2023; 13():1077675. PubMed ID: 37114136
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
Huo G; Liu W; Chen P
BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
Front Oncol; 2022; 12():924149. PubMed ID: 35719979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
